Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > NanoViricides Becomes a Member Of Alliance for Biosecurity

Abstract:
NanoViricides, Inc., a nano-biopharmaceutical company specializing in the development of novel therapeutics to treat life-threatening viral infections, announced today that it has joined the Alliance for Biosecurity, an association comprised of a leading non-profit biosecurity organization and 14 other biopharmaceutical companies committed to improving the nation's biosecurity through the development of medical countermeasures to address a range of bioterrorism and natural pandemic threats.

NanoViricides Becomes a Member Of Alliance for Biosecurity

WEST HAVEN, CT | Posted on April 16th, 2007

Anita Cicero, Executive Director of the Alliance for Biosecurity, commented, "We are delighted to welcome NanoViricides into the Alliance. The company's work in the cutting-edge field of Nanomedicine, combined with its interest in contributing constructive policy suggestions to bolster national Flexible Defense initiatives, will be a significant asset to the Alliance. NanoViricides shares our organization's goal of rapidly accelerating the research, development, and procurement of medical countermeasures that will be needed to respond to both destabilizing pandemics and bioterrorism attacks. With NanoViricides' help, the Alliance will continue its efforts to maximize the promise of Project BioShield and the new Pandemic and All Hazards Preparedness Act."

"Our Rapid Response technologies fit in well with the Flexible Biodefense initiatives that are part of recent US Government acts," said Anil R. Diwan, Ph.D., President, NanoViricides, Inc.

"NanoViricides is honored to be associated with this prestigious organization whose strong membership, comprised of the principal actors in the BioSecurity field, includes some of the most prestigious pharma and biotechnology companies in the world," added Dr. Eugene Seymour, CEO, NanoViricides, Inc.

In other news, NanoViricides, Inc. announced that it has been informed that the nominating NASD member firm has responded to NASD comments on the form 15c2-11submission for NanoViricides to be listed on the over the counter bulletin board (OTC-BB).

####

About NanoViricides
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.

About the Alliance for Biosecurity- http://www.allianceforbiosecurity.org

The Alliance for Biosecurity is a collaboration among the Center for Biosecurity of the University of Pittsburg Medical Center, pharmaceutical companies, and biotechnology companies working to develop new technologies and vaccines and medicines for the Strategic National Stockpile. The Alliance seeks to engage government in a public-private partnership to usher in a new era in the prevention and treatment of severe infectious diseases that present global security threats. Member companies of the Alliance now include: Acambis, Inc., Avecia Biotechnology, Bavarian-Nordic, Cangene Corporation, DOR BioPharma, Inc., DynPort Vaccine Company, LLC, a CSC company, Elusys Therapeutics, Inc., Emergent BioSolutions, GlaxoSmithKline, Human Genome Sciences, Inc., Iomai Vaccines, NanoViricides, Inc., Novartis Vaccines & Diagnostics, Pfizer Inc., and PharmAthene, Inc.

For more information, please click here

Contacts:
NanoViricides, Inc.
Leo Ehrlich, 917-853-6440

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Alliances/Trade associations/Partnerships/Distributorships

Manchester graphene spin-out signs $1billion game-changing deal to help tackle global sustainability challenges: Landmark deal for the commercialisation of graphene April 14th, 2023

Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022

CEA & Partners Present ‘Powerful Step Towards Industrialization’ Of Linear Si Quantum Dot Arrays Using FDSOI Material at VLSI Symposium: Invited paper reports 3-step characterization chain and resulting methodologies and metrics that accelerate learning, provide data on device pe June 17th, 2022

University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project